Literature DB >> 9409335

Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?

S M Resnick1, E J Metter, A B Zonderman.   

Abstract

Estrogen replacement therapy (ERT) is increasingly recommended for postmenopausal women due to its beneficial effects on physical health in older women. Recent studies have suggested that ERT may have a protective effect on cognitive function and may reduce the risk of Alzheimer's disease. In the present study we test the hypothesis that ERT may have a protective effect on memory in nondemented women. Data on hormonal status and memory were examined in 288 postmenopausal women in the Baltimore Longitudinal Study of Aging. One hundred sixteen women who reported that they were receiving ERT during a cognitive assessment were compared with 172 women who had never received ERT. Women who were receiving ERT had fewer errors on the Benton Visual Retention Test (BVRT), a measure of short-term visual memory, visual perception, and constructional skills. Furthermore, ERT appeared to protect against age changes in BVRT performance in a subgroup of 18 women for whom BVRT data were available before and during treatment with ERT. These findings suggest that ERT may protect against memory decline in nondemented postmenopausal women and offer further support for a beneficial role of estrogen on cognitive function in aging women.

Entities:  

Mesh:

Year:  1997        PMID: 9409335     DOI: 10.1212/wnl.49.6.1491

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

Review 1.  HRT and its effect on normal ageing of the brain and dementia.

Authors:  J Compton; T van Amelsvoort; D Murphy
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 2.  Impact of estrogen therapy on Alzheimer's disease: a fork in the road?

Authors:  Roberta D Brinton
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

4.  Administration of dehydroepiandrosterone (DHEA) enhances visual-spatial performance in postmenopausal women.

Authors:  Bethany Stangl; Elliot Hirshman; Joseph Verbalis
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

5.  Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women.

Authors:  Paul A Newhouse; Julie Dumas; Heather Wilkins; Emily Coderre; Cynthia K Sites; Magdalena Naylor; Chawki Benkelfat; Simon N Young
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

6.  Sex differences in visuospatial abilities persist during induced hypogonadism.

Authors:  Gioia M Guerrieri; Paul G Wakim; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn J Gibson; David R Rubinow; Peter J Schmidt
Journal:  Neuropsychologia       Date:  2015-12-21       Impact factor: 3.139

7.  Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy.

Authors:  Carol C Persad; Jon-Kar Zubieta; Tiffany Love; Heng Wang; Anne Tkaczyk; Yolanda R Smith
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

Review 8.  Estrogen: a master regulator of bioenergetic systems in the brain and body.

Authors:  Jamaica R Rettberg; Jia Yao; Roberta Diaz Brinton
Journal:  Front Neuroendocrinol       Date:  2013-08-29       Impact factor: 8.606

9.  Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial.

Authors:  Niels Bergemann; Peter Parzer; Susanne Jaggy; Beatrice Auler; Christoph Mundt; Sabine Maier-Braunleder
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

10.  A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics.

Authors:  Mary Sano; Diane Jacobs; Howard Andrews; Karen Bell; Neill Graff-Radford; John Lucas; Peter Rabins; Karen Bolla; Wei-Yan Tsai; Peter Cross; Karen Andrews; Rosann Costa
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.